A pilot study of circulating PPAR-γ receptor protein in elderly patients with atrial fibrillation

Archives of Medical Science

Volumn 8, Issue 3, 2012, Pages 471-476

  Lin, Qing ^a   Jia, Lina ^b   Sun, Yanshu ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Inflammation; Peroxisome proliferator activated receptor

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; INFLAMMATION; INFORMED CONSENT; MALE; PATHOGENESIS; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR; SINUS RHYTHM;

EID: 84863899931     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.29402     Document Type: Article

References (22)

1. Aksnes TA, Kjeldsen SE, Julius S. Atrial fibrillation and hypertension. Arch Med Sci 2009; 5: S267-72.
2. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin 2009; 27: 13-24, vii.
3. Banach M, Misztal M, Goch A, Rysz J, Goch JH. Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28786 patients. Arch Med Sci 2007; 3: 229-39. (Pubitemid 47621670)
4. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 2009; 157: 243-52.
5. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7: 438-44.
6. Rosiak M, Dziuba M, Chudzik M, et al. Risk factors for atrial fibrillation: not always severe heart disease, not always so 'lonely'. Cardiol J 2010; 17: 437-42.
7. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007; 49: 1642-8. (Pubitemid 46551628)
8. Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004; 45: 441-5. (Pubitemid 41518887)
9. Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm 2009; 6: 454-60.
10. Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43: 292-7.
11. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35. (Pubitemid 34177889)
12. Zieleniak A, Wójcik M, Woźniak LA. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) 2008; 56: 331-45.
13. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 2007; 28: 551-8. (Pubitemid 350101420)
14. Robinson E, Grieve DJ. Significance of peroxisome proliferator- activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009; 122: 246-63.
15. Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator- activated receptor-gamma in atherosclerosis: an update. Circ J 2011; 75: 528-5.
16. Zhu HL, Yu RM, Huang XZ, Huang W. Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1050-1.
17. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007; 49: 290-7. (Pubitemid 46110954)
18. Chen X, Bing Z, He J, et al. Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. Clin Cardiol 2009; 32: 337-45.
19. Aldhoon B, Melenovský V, Peichl P, Kautzner J. New insights into mechanisms of atrial fibrillation. Physiol Res 2010; 59: 1-12.
20. Kume O, Takahashi N, Wakisaka O, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011; 8: 278-85.
21. Shimano M, Tsuji Y, Inden Y, et al Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008; 5: 451-9.
22. Gu J, Liu X, Wang X, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011; 13: 1256-61.